Results 51 to 60 of about 8,209 (210)

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Global & Regional Health Technology Assessment, 2021
Purpose: The objective of this economic evaluation was to compare the cost per responder between upadacitinib and abatacept (intravenous [iv] or subcutaneous [sc]) in patients with moderate-to-severe Rheumatoid Arthritis (RA) in Italy.
Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi   +3 more
doaj   +1 more source

Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son, Yves Julien Mbama Biloa, Pauline Gouttefarde, Thomas Franck, Gilles Cizeron, Mathieu Oriol, François Maccari, Elisa Cinotti, Beatrice Trombert‐Paviot, Bienvenu Bongue, Jean‐Luc Perrot   +10 more
wiley   +1 more source

Upadacitinib in Active Non‐radiographic Axial Spondyloarthritis: 1‐Year Data From a Double‐Blind, Randomized, Placebo‐Controlled, Phase 3 Trial

ACR Open Rheumatology
Objective Upadacitinib improved the signs and symptoms of non‐radiographic axial spondyloarthritis (nr‐axSpA) versus placebo over 14 weeks in the primary analysis of the SELECT‐AXIS 2 nr‐axSpA study.
Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van derHeijde, Tae‐Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Yihan Li, Kristin D'Silva, Peter Wung, In‐Ho Song   +11 more
doaj   +1 more source

Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort [PDF]

, 2023
Background: Upadacitinib was the first JAK-1 selective inhibitor registered for the treatment of moderate-to-severe atopic dermatitis (AD). Although efficacy and safety have been shown in clinical trials, real-world data on the use of upadacitinib in ...
Boeijink, Neill, Hijnen, Dirk Jan, Nijsten, Tamar E.C., Olydam, Jill, Schlösser, Anne R.   +4 more
core   +2 more sources

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Intensified Upadacitinib Dosing for Adolescent Patients with Acute Severe Ulcerative Colitis

Children
Background/Objectives: In adolescent patients with ulcerative colitis refractory to anti-tumor necrosis factor (TNF) therapy, episodes of acute severe ulcerative colitis (ASUC) require hospitalization or surgery. Upadacitinib can be a potential colectomy-
Perseus V. Patel, Martina Rigmaiden, Alka Goyal, Rachel Bensen, Dorsey Bass, Jonathan Moses, Michael J. Rosen, Ruben J. Colman   +7 more
doaj   +1 more source

Upadacitinib: Mechanism of action, clinical, and translational science

Clinical and Translational Science
Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food and Drug Administration, the European Medicines Agency, as well as other agencies around the world for the treatment of several chronic inflammatory diseases ...
Mohamed‐Eslam F. Mohamed, Sumit Bhatnagar, Julie M. Parmentier, Priscila Nakasato, Peter Wung   +4 more
doaj   +1 more source

Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea

Frontiers in Immunology
IntroductionConventional rosacea treatments are not uniformly pervasive, and the adverse reactions can potentially constrain their utility. The clinical use of JAK1 inhibitors upadacitinib and abrocitinib in the treatment of refractory rosacea has rarely
Ting Zhang, Xu Liu, Lu Zhang, Xian Jiang, Xian Jiang   +4 more
doaj   +1 more source

Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data [PDF]

The advent of Janus kinase (JAK) inhibitors, including tofacitinib, filgotinib, and upadacitinib, has significantly widened the therapeutic options for patients with inflammatory bowel disease (IBD).
Alfredo Papa, Angelo Del Gaudio, Antonio Gasbarrini, Franco Scaldaferri, Gaetano Coppola, Jacopo Iaccarino, Loris Riccardo Lopetuso, Lucrezia Laterza, Pierluigi Puca, Stefania Colantuono, Valentina Blasi   +10 more
core   +1 more source

Concurrent Psoriasis and Dermatomyositis: Retrospective Analysis and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis (PsO) and dermatomyositis (DM) are both autoimmune‐mediated, inflammatory conditions. The concurrence of PsO and DM is rare, and literature on their relationship remains limited. Additionally, cutaneous DM can be challenging to clinically diagnosis, often presenting with psoriasiform clinical features.
Emily R. Gordon, Karishma S. Shah, Sidharth Chand, Bonnie Lee, Janellen Smith, Michelle S. Min   +5 more
wiley   +1 more source